Incyte (INCY) Cash from Operations Growth (1y) (2011 - 2026)
Incyte (INCY) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 158.60% |
| 10 | Incyte | 23.89 Bn | 19.88 Bn | 1.17 Bn | 38.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.82% |
| Dec 31, 2025 | 42.52% |
| Sep 30, 2025 | 79.94% |
| Jun 30, 2025 | 107.77% |
| Mar 31, 2025 | 21.60% |
| Dec 31, 2024 | 158.05% |
| Sep 30, 2024 | 110.28% |
| Jun 30, 2024 | -287.77% |
| Mar 31, 2024 | 307.20% |
| Dec 31, 2023 | -47.92% |
| Sep 30, 2023 | -50.12% |
| Jun 30, 2023 | 76.01% |
| Mar 31, 2023 | -148.95% |
| Dec 31, 2022 | 145.91% |
| Sep 30, 2022 | 16.18% |
| Jun 30, 2022 | 0.70% |
| Mar 31, 2022 | 4.68% |
| Dec 31, 2021 | 7.48% |
| Sep 30, 2021 | 40.08% |
| Jun 30, 2021 | -35.80% |